摘要
目的:探究帕博利珠单抗联合化疗治疗晚期肝内胆管细胞癌的效果及对肿瘤标志物的影响。方法:将2021年7月-2022年6月九江市第一人民医院收治的80例晚期肝内胆管细胞癌患者根据随机数字表法分为对照组和观察组,各40例。对照组进行常规化疗,观察组进行帕博利珠单抗联合化疗。比较两组客观缓解率、毒副反应发生率及治疗前后的凋亡因子[X-连锁凋亡抑制蛋白(XIAP)及线粒体促凋亡蛋白(Smac)]及肿瘤标志物[糖类抗原19-9(CA19-9)、糖类抗原125(CA125)及癌胚抗原(CEA)]水平。结果:观察组客观缓解率显著高于对照组,毒副反应发生率显著低于对照组,差异均有统计学意义(P<0.05)。治疗前两组凋亡因子及肿瘤标志物水平比较,差异均无统计学意义(P>0.05);治疗4、8个周期后,观察组Smac均显著高于对照组,XIAP及肿瘤标志物均显著低于对照组,差异均有统计学意义(P<0.05)。结论:帕博利珠单抗联合化疗治疗晚期肝内胆管细胞癌的效果较好,可更为有效地控制肿瘤标志物水平。
Objective:To investigate the effect of Pembrolizumab combined with chemotherapy on advanced intrahepatic cholangiocarcinoma and its influence on tumor markers.Method:A total of 80 patients with advanced intrahepatic cholangiocarcinoma admitted to Jiujiang NO.1 People's Hospital from July 2021 to June 2022 were divided into a control group and an observation group according to the random number table method,40 cases in each group.The control group was treated with routine chemotherapy,and the observation group was treated with Pembrolizumab combined with chemotherapy.The objective response rate,incidence of adverse reactions,before and after treatment of levels of apoptotic factors[X-linked inhibitor of apoptosis protein(XIAP)and second mitochondria-derived activator of caspases(Smac)]and tumor markers[carbohydrate antigen 19-9(CA19-9),carbohydrate antigen 125(CA125)and carcinoembryonic antigen(CEA)]were compared between the two groups.Result:The objective response rate of the observation group was significantly higher than that of the control group,and the incidence of toxic side effects was significantly lower than that of the control group,the differences were statistically significant(P<0.05).There were no significant differences in the levels of apoptotic factors and tumor markers between the two groups before treatment(P>0.05).After 4 or 8 cycles of treatment,the Smac in the observation group were significantly higher than those in the control group,and the XIAP and tumor markers were significantly lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Pembrolizumab combined with chemotherapy is effective in the treatment of advanced intrahepatic cholangiocarcinoma,which can control the level of tumor markers more effectively.
作者
邓建华
赵新华
DENG Jianhua;ZHAO Xinhua(Jiujiang NO.1 People's Hospital,Jiangxi Province,Jiujiang 332000,China;不详)
出处
《中国医学创新》
CAS
2023年第16期1-4,共4页
Medical Innovation of China
基金
江西省卫生健康委科技计划项目(SKJP220210248)。
关键词
肝内胆管细胞癌
帕博利珠单抗
化疗
肿瘤标志物
Intrahepatic cholangiocarcinoma
Pembrolizumab
Chemotherapy
Tumor markers
